2 weeks Ago By Defense World Staff
American Century Companies Inc. trimmed its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 18.
5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 85,466 shares of the specialty pharmaceutical company’s stock after selling 19,447 shares during the quarter. American Century Companies Inc.
owned about 0.27% of Collegium Pharmaceutical worth $2,449,000 as of its most recent filing with the Securities and Exchange Commission. A number of other hedge funds and other institutional investors also recently made changes to their positions in COLL.
TD Private Client Wealth LLC increased its stake in shares of Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after acquiring an additional 483 shares during the period.
KBC Group NV lifted its position in Collegium Pharmaceutical by 72.5% in the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after purchasing an additional 982 shares during the period.
Nisa Investment Advisors LLC boosted its stake in Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 316 shares in the last quarter.
China Universal Asset Management Co. Ltd. increased its position in shares of Collegium Pharmaceutical by 10.
4% during the 4th quarter. China Universal Asset Management Co. Ltd.
now owns 6,838 shares of the specialty pharmaceutical company’s stock valued at $196,000 after purchasing an additional 642 shares during the period. Finally, Aigen Investment Management LP acquired a new position in shares of Collegium Pharmaceutical during the 4th quarter valued at $230,000. Collegium Pharmaceutical Trading Down 2.
7 %Shares of NASDAQ COLL opened at $27.38 on Tuesday. The company has a quick ratio of 0.
88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43.
Collegium Pharmaceutical, Inc. has a 12 month low of $26.64 and a 12 month high of $42.
29. The company has a market cap of $879.77 million, a price-to-earnings ratio of 11.
80 and a beta of 0.76. The business has a fifty day simple moving average of $29.
88 and a 200-day simple moving average of $32.03. Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last posted its quarterly earnings data on Thursday, February 27th.
The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.
09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.
67%. The company had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.
68 million. Sell-side analysts predict that Collegium Pharmaceutical, Inc. will post 5.
62 EPS for the current year. Wall Street Analysts Forecast GrowthSeveral brokerages recently weighed in on COLL. Piper Sandler decreased their target price on Collegium Pharmaceutical from $37.
00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. HC Wainwright restated a “buy” rating and set a $50.
00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Finally, Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a report on Friday, January 10th.
One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $43.
60.View Our Latest Stock Analysis on COLLInsider Buying and SellingIn related news, CFO Colleen Tupper sold 10,445 shares of the company’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $30.
01, for a total transaction of $313,454.45. Following the transaction, the chief financial officer now directly owns 165,246 shares of the company’s stock, valued at approximately $4,959,032.
46. The trade was a 5.95 % decrease in their ownership of the stock.
The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the firm’s stock in a transaction dated Tuesday, March 4th.
The stock was sold at an average price of $28.08, for a total value of $1,123,200.00.
Following the sale, the executive vice president now owns 154,204 shares of the company’s stock, valued at $4,330,048.32. The trade was a 20.
60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 109,193 shares of company stock valued at $3,243,594.
Company insiders own 3.98% of the company’s stock. Collegium Pharmaceutical Profile (Free Report)Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.See AlsoFive stocks we like better than Collegium PharmaceuticalProcter & Gamble (NYSE:PG) Pulls Back After Shaky GuidanceOptions Activity Points to More Volatility for Palantir StockWhat Does a Gap Up Mean in Stocks? How to Play the GapNVIDIA Stock: Oversold, Undervalued — How Low Can It Go?How to Invest in the Best Canadian Stocks MicroStrategy Sees Insider Buy-Sell Action in Q1Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc.
(NASDAQ:COLL – Free Report)..
